ArticleCritical care (London, England)2011
The desperate need for good-quality clinical trials to evaluate the optimal source and dose of fibrinogen in managing bleeding.
Article in Critical care (London, England), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Fibrinogen concentrate in bleeding patients.The Cochrane database of systematic reviews · 2013Pooled it
- Fibrinogen Early In Severe Trauma studY (FEISTY): study protocol for a randomised controlled trial.Trials · 2017Trial
- Trial
- Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery.British journal of anaesthesia · 2013Trial
- Fibrinogen Early In Severe Trauma studY (FEISTY): results from an Australian multicentre randomised controlled pilot trial.Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine · 2021Article
- Over 50 Years of Fibrinogen Concentrate.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis · 2016Review
- Prevalence, predictors and outcome of hypofibrinogenaemia in trauma: a multicentre observational study.Critical care (London, England) · 2014Observational
- Changes in fibrinogen availability and utilization in an animal model of traumatic coagulopathy.Scandinavian journal of trauma, resuscitation and emergency medicine · 2013Article
- Haemostatic monitoring during postpartum haemorrhage and implications for management.British journal of anaesthesia · 2012Review
- Emotional or evidence-based medicine--is there a moral tragedy in haemostatic therapy?Critical care (London, England) · 2011Article
Corrections and comments
- Commented on by
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent interest in transfusion management of trauma patients has heightened expectation in the role of blood component therapy in improving patient outcome. Optimal transfusion support in supplementation with fibrinogen has not been defined by high-quality evidence. Current evidence comes mainly from case series and uncontrolled studies and does not support the superiority of one source of fibrinogen over another or the optimal schedule or dose for patient benefit. There are unanswered questions about safety, especially the effects on the risk of hospital-acquired venous thromboembolism, an important consideration in any therapy that alters the hemostatic balance. Studies of cost-effectiveness have not been considered in research. An international move to supplement fibrinogen more 'aggressively' without direct clinical evaluation beforehand represents a failed opportunity to improve our very limited understanding of optimal transfusion practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.